Key result
Novokinin, perindopril, and losartan lower blood pressure and reduce renal NADPH oxidase and ADMA levels.
Why the study?
Does novokinin, perindopril, or losartan improve blood pressure and renal tissue biomarkers in an L-NAME and salt-induced hypertension model?
Does novokinin, perindopril, or losartan improve blood pressure and renal tissue biomarkers in an L-NAME and salt-induced hypertension model?
The AT2 receptor agonist novokinin, similar to perindopril and losartan, reduces blood pressure and improves renal tissue biomarkers in a model of L-NAME and salt-induced hypertension, suggesting potential end-organ protection.
Novokinin improves BP and endothelial function in L-NAME/salt hypertensive rats; leaves open clinical effects on renal ADMA or Rho kinase.
There is no sufficiently investigation about the effects of novokinin, AT2 receptor agonist, on target molecules associated with organ pathology including ADMA, NADPH oxidase and Rho kinase.In this study we investigated the effects of novokinin, perindopril and losartan on Rho kinase, ADMA, NADPH oxidase at renal tissue blood pressure, in L-NAME and salt induced hypertension.Additionally, a1-adrenergic-induced contraction, ach-induced dilator responses in vessels obtained from hypertensive and pharmacological therapy groups were studied.In this study we investigated the effects of novokinin, perindopril and losartan on blood pressure, Rho kinase, ADMA, NADPH oxidase at renal tissue in L-NAME and salt induced hypertension.Additionally, a1-adrenergic-induced contraction, ach-induced dilator responses in vessels obtained from hypertensive and pharmacological therapy groups were studied.To develop hypertension, L-NAME was administrated intraperitoneally and drinking water with salt (1%) for 4 weeks.Perindopril, losartan, novokinin were administrated intraperitoneally for 2 weeks.Blood pressure was measured by using tail-cuff method; Rho kinase, ADMA and NADPH oxidase were measured by ELİSA at renal tissues.Values are presented as means ± S.E.M.; compared by one way anova.Novokinin, perindopril and losartan diminished the level of NADPH oxidase and ADMA at renal tissue compared to hypertension group.Novokinin, perindopril and losartan decreased blood pressure.The greatest reduction of blood pressure was determined in perindopril treatment group In the hypertensive group, the acetylcholine EC50 value was significantly higher than in the control group and Emax value was significantly lower in hypertensive group compared to control.The application of novokinin, perindopril and losartan were improved the ach induced dilator responses in L-NAME and salt induced hypertension model.AT2 receptor agonist novokinin may offer protection of target organs such as the kidney.In this regard, further experimental studies are needed to exhibit potential benefits of novokinin in hypertension and end organ damage treatment for advanced clinical research.
No takes yet. Share an insight, caveat, or question.
Mutlu et al. (2015) studied L-NAME and salt induced hypertension. Novokinin, perindopril and losartan vs. Hypertension control group was evaluated on Blood pressure, Rho kinase, ADMA, and NADPH oxidase levels at renal tissue. Novokinin, perindopril, and losartan decreased blood pressure and diminished NADPH oxidase and ADMA levels in renal tissue compared to the hypertension control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: